🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ke Liu

Nanjing University of Chinese Medicine

ORCID: 0000-0002-4683-9325

Also affiliated with Tianjin University of Science and Technology, Central South University, Second Military Medical University, Shenzhen University, Yantai University, Dalian Medical University, Chinese Academy of Sciences, Sichuan University, Leshan Normal University, Southern University of Science and Technology, Wuhan University, West China Hospital of Sichuan University, Shanghai CASB Biotechnology (China), Second Affiliated Hospital of Chongqing Medical University, Zhejiang Cancer Hospital, Shanghai Veterinary Research Institute, Shanghai Changzheng Hospital, Nanfang Hospital, Xi'an Medical University, Shanghai Advanced Research Institute, Hunan Cancer Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Advanced Energy Materials (United States), Stomatology Hospital, Henan Provincial People's Hospital, Berry Oncology (China), PharmacoGenetics (China), Shenzhen Institutes of Advanced Technology, Zhengzhou People's Hospital, Io Therapeutics (United States), Shenzhen Technology University, Chongqing Academy of Agricultural Sciences, Second Affiliated Hospital of Zhejiang University, Xiangya Hospital Central South University, University of Chinese Academy of Sciences, Ningbo Institute of Industrial Technology, Hangzhou Medical College, Systèmes avancés de délivrance de principes actifs, Southern Medical University, Zhejiang University, Yangzhou University, Nanjing Medical University, Chongqing Medical University

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.

14 citations

Yongsoek Park, Ke Liu, Bin Zhu, Zhenzhen Xu

9 citations

Jie Lu, Hung‐Chun Tung, Ke Liu, Jianhua Li, Denis M. Grant +3 more

20 citations

Shang Su, Jing Xing, Ke Liu, Yawei Zhao, Mary M. Stangis +6 more